Diplomat Pharmacy (DPLO) Misses Q4 Revenues Below Estimates; Lowers FY19 Revenue Guidance Below Consensus, Offers FY19 EPS Guidance Below Consensus

Diplomat Pharmacy (NYSE: DPLO) reported Q4 EPS of ($4.00), $4.23 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $1.36 billion versus the consensus estimate of $1.41 billion.

Brian Griffin, Chairman and CEO of Diplomat, commented "While our 2018 financial results were strong, market conditions in 2019 are significantly more challenging than expected in our specialty and PBM businesses. 2019 is a rebuilding year, and we continue to focus on driving additional volumes to Diplomat by creating partnerships with health plans and hospital systems to meet the demand for better clinical outcomes and management of specialty spend. We are also committed to rebuilding our PBM business."

GUIDANCE:

Diplomat Pharmacy sees FY2019 EPS of ($0.50)-($0.34), versus the consensus of $0.61. Diplomat Pharmacy sees FY2019 revenue of $4.7-5 billion, versus the consensus of $5 billion.

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping drops bid for Genco after price demands spike to $36.91
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c